Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. The 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) of PepGen Inc. (the “Company”) was held on June 18, 2026.…
Filed Jun 22, 2026Accepted Jun 22, 2026, 4:30 PM EDTCIK 1835597Accession 0001193125-26-277579
PepGen Inc. is a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, PepGen is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders.
The 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) of PepGen Inc. (the “Company”) was held on June 18, 2026. The proposals set forth below were submitted to the stockholders at the 2026 Annual Meeting, with each such proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2026 in connection with the 2026 Annual Meeting.
The number of shares of common stock entitled to vote at the 2026 Annual Meeting was 69,169,215. The number of shares of common stock present or represented by valid proxy at the 2026 Annual Meeting was 54,650,845. Therefore, a quorum was present. The number of votes cast for and withheld/against and the number of abstentions and broker non-votes with respect to each proposal voted upon are set forth below.
Proposal 1 - Election of Directors
The Company’s stockholders elected the three Class I directors to the Company’s board of directors, to serve until the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal.
Director Nominee Votes For Votes Withheld
────────────────────────────────────────────────────────────────────
Howard Mayer, M.D. 36,111,969 8,502,248
Joshua Resnick, M.D., M.B.A. 35,766,232 8,847,985
Lisa Wyman, M.S. 39,423,497 5,190,720
There were 10,036,628 broker non-votes regarding the election of each of Howard Mayer, Joshua Resnick, and Lisa Wyman.
Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm
The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Votes For Votes Against Abstentions
──────────────────────────────────────────────────
54,556,255 77,083 17,507
There were zero broker non-votes regarding this proposal.